| March 2005 · Vol. 17, No. 3 UPDATE on CERVICAL DISEASE
New Developments That Are Changing Patient Care
Get ready for a practice makeover
HPV vaccine imminent … Colposcopy disappoints … LEEP raises preterm risk … LSIL meaningless?
Thomas
C.
Wright
Jr,
MDAssociate Professor of Pathology,
College of Physicians and Surgeons,
Columbia University,
New York City
Dr. Wright participated in the Bethesda 3 Conference on Reporting Cervical Cytologic Results, and in developing the American Society for Colposcopy and Cervical Pathology Consensus Guidelines
As soon as next year, the human papillomavirus (HPV) vaccine could transform clinical practice more than anything since the Pap smear was introduced 60 years ago.
A second large trial has shown extraordinary efficacy, and now 2 manufacturers, GlaxoSmithKline and Merck, are conducting late-phase clinical trials and working toward registering their vaccines for clinical use in 2006. Only last month, Merck and GSK signed an agreement that resolves their competing intellectual property claims—removing one more barrier to rapid commercialization.
|
